05178nam 22008055 450 991029834930332120200703210745.01-4899-8056-310.1007/978-1-4899-8056-4(CKB)3710000000087958(EBL)1698301(OCoLC)880448075(SSID)ssj0001185997(PQKBManifestationID)11654415(PQKBTitleCode)TC0001185997(PQKBWorkID)11217417(PQKB)11700207(MiAaPQ)EBC1698301(DE-He213)978-1-4899-8056-4(PPN)176749837(EXLCZ)99371000000008795820140210d2014 u| 0engur|n|---|||||txtccrTumor-Induced Immune Suppression[electronic resource] Mechanisms and Therapeutic Reversal /edited by Dmitry I. Gabrilovich, Arthur Andrew Hurwitz2nd ed. 2014.New York, NY :Springer New York :Imprint: Springer,2014.1 online resource (471 p.)Description based upon print version of record.1-4899-8055-5 Includes bibliographical references at the end of each chapters and index.Preface.- Regulatory T Cells and Cancer -- Th17 cells in cancer -- Mast cells and immune response in cancer -- Myeloid-Derived Suppressor Cells in Tumor-Induced T-Cell Suppression and Tolerance -- Immunobiology of Dendritic Cells in Cancer -- Macrophages and Tumor Development -- Angiogenesis and Immune Suppression in Cancer -- Tim-3 Regulation of Cancer Immunity.- Transcriptional Regulation of Dendritic Cells in The Tumor Microenvironment -- S100A9, Inflammation, and Regulation of Immune Suppression in Cancer -- IDO in Inflammatory Programming and Immune Suppression in Cancer -- Defining the Fate and Function of Effector T cells through Galectin-1 – Galectin-1 Ligand Binding Interactions: Implications in Tumor Immunity -- Arginine Metabolism, a Major Pathway for the Suppressive Function of Myeloid-derived Suppressor Cells.- The Hypoxia-Adenosinergic Immunosuppression and Redirection of Immune Response in Tumor Microenvironment -- Molecular Pathways in Antigen Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance -- Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer -- Index.Tumor-Induced Immune Suppression - Prospects and Progress in Mechanisms and Therapeutic Reversal presents a comprehensive overview of large number of different mechanisms of immune dysfunction in cancer  and therapeutic approaches to their correction. This includes the number of novel mechanisms that has never before been discussed in previous monographs. The last decades were characterized by substantial progress in the understanding of the role of the immune system in tumor progression. Researchers have learned how to manipulate the immune system to generate tumor specific immune response, which raises high expectations for immunotherapy  to provide breakthroughs in cancer treatment.  It is increasingly clear that tumor-induced abnormalities in the immune system not only hampers natural tumor immune surveillance,  but also limits the effect of cancer immunotherapy. Therefore, it is critically important to understand the mechanisms of tumor-induced immune  suppression to make any progress in the field and this monograph provides these important insights.Cancer researchImmunologyMedical microbiologyCell biologyHuman geneticsDevelopmental biologyCancer Researchhttps://scigraph.springernature.com/ontologies/product-market-codes/B11001Immunologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B14000Medical Microbiologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B16003Cell Biologyhttps://scigraph.springernature.com/ontologies/product-market-codes/L16008Human Geneticshttps://scigraph.springernature.com/ontologies/product-market-codes/B12008Developmental Biologyhttps://scigraph.springernature.com/ontologies/product-market-codes/L18000Cancer research.Immunology.Medical microbiology.Cell biology.Human genetics.Developmental biology.Cancer Research.Immunology.Medical Microbiology.Cell Biology.Human Genetics.Developmental Biology.571.6571.8599935610Gabrilovich Dmitry Iedthttp://id.loc.gov/vocabulary/relators/edtHurwitz Arthur Andrewedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910298349303321Tumor-Induced Immune Suppression2508872UNINA